Published in Int J Cancer on September 15, 1989
Animal models of ovarian cancer. Reprod Biol Endocrinol (2003) 1.57
Tumorgrafts as in vivo surrogates for women with ovarian cancer. Clin Cancer Res (2014) 1.35
Xenograft and Transgenic Mouse Models of Epithelial Ovarian Cancer and Non Invasive Imaging Modalities to Monitor Ovarian Tumor Growth In situ -Applications in Evaluating Novel Therapeutic Agents. Curr Protoc Pharmacol (2009) 1.06
Current status and evolution of preclinical drug development models of epithelial ovarian cancer. Front Oncol (2013) 0.98
A xenograft mouse model coupled with in-depth plasma proteome analysis facilitates identification of novel serum biomarkers for human ovarian cancer. J Proteome Res (2011) 0.95
A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer. J Clin Invest (1993) 0.94
Modeling High-Grade Serous Carcinoma: How Converging Insights into Pathogenesis and Genetics are Driving Better Experimental Platforms. Front Oncol (2013) 0.91
Establishment of an orthotopic transplantation tumor model of hepatocellular carcinoma in mice. World J Gastroenterol (2012) 0.90
Patient-derived xenograft models in gynecologic malignancies. Am Soc Clin Oncol Educ Book (2014) 0.90
Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models. Br J Cancer (2012) 0.86
7,12-dimethylbenz[a]anthracene-induced malignancies in a mouse model of menopause. Comp Med (2013) 0.83
The promise and challenge of ovarian cancer models. Transl Cancer Res (2015) 0.82
Advances in tumor screening, imaging, and avatar technologies for high-grade serous ovarian cancer. Front Oncol (2014) 0.82
The development of a novel immunotherapy model of human ovarian cancer in human PBL-severe combined immunodeficient (SCID) mice. Clin Exp Immunol (1995) 0.79
Establishment of a new representative model of human ovarian cancer in mice. J Ovarian Res (2013) 0.79
Histologic and molecular analysis of patient derived xenografts of high-grade serous ovarian carcinoma. J Hematol Oncol (2016) 0.77
Cediranib combined with chemotherapy reduces tumor dissemination and prolongs the survival of mice bearing patient-derived ovarian cancer xenografts with different responsiveness to cisplatin. Clin Exp Metastasis (2015) 0.76
Establishment and characterization of intraperitoneal xenograft models by co-injection of human tumor cells and extracellular matrix gel. Oncol Lett (2015) 0.75
Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models. Br J Cancer (2017) 0.75
Inflammation and cancer: back to Virchow? Lancet (2001) 27.40
Roots of clinical resistance to STI-571 cancer therapy. Science (2001) 9.78
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet (2003) 8.88
Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med (1998) 8.56
Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet (1997) 6.53
Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation. Science (2000) 6.26
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst (2000) 5.62
Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood (1996) 5.31
The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med (1995) 4.75
Tumor necrosis factor is chemotactic for monocytes and polymorphonuclear leukocytes. J Immunol (1987) 4.75
Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol (2009) 4.53
Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity (1997) 4.19
Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. Blood (1992) 4.11
Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. J Immunol (2000) 4.07
The human toll signaling pathway: divergence of nuclear factor kappaB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6). J Exp Med (1998) 3.70
Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science (1993) 3.62
Bacterial lipopolysaccharide activates nuclear factor-kappaB through interleukin-1 signaling mediators in cultured human dermal endothelial cells and mononuclear phagocytes. J Biol Chem (1999) 3.53
Monoclonal antibodies specific for endothelial cells of mouse blood vessels. Their application in the identification of adult and embryonic endothelium. Eur J Cell Biol (1994) 3.31
IL-1 stimulates IL-6 production in endothelial cells. J Immunol (1989) 2.85
Selective up-regulation of chemokine receptors CCR4 and CCR8 upon activation of polarized human type 2 Th cells. J Immunol (1998) 2.84
Differential regulation of chemokine receptors during dendritic cell maturation: a model for their trafficking properties. J Immunol (1998) 2.70
Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor. J Cell Biol (1990) 2.69
Interleukin 1 signaling occurs exclusively via the type I receptor. Proc Natl Acad Sci U S A (1993) 2.67
Cytokines as communication signals between leukocytes and endothelial cells. Immunol Today (1989) 2.60
The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res (1996) 2.57
Properties of monocyte chemotactic and activating factor (MCAF) purified from a human fibrosarcoma cell line. J Exp Med (1990) 2.40
Human macrophage-derived chemokine (MDC), a novel chemoattractant for monocytes, monocyte-derived dendritic cells, and natural killer cells. J Exp Med (1997) 2.37
Class II versus class III radical hysterectomy in stage IB-IIA cervical cancer: a prospective randomized study. Gynecol Oncol (2001) 2.34
Growth and metastasis of tumor cells isolated from a human renal cell carcinoma implanted into different organs of nude mice. Cancer Res (1986) 2.30
Granulocyte- and granulocyte-macrophage-colony stimulating factors induce human endothelial cells to migrate and proliferate. Nature (1989) 2.25
PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation (2000) 2.19
Focal cortical dysplasia: neuropathological subtypes, EEG, neuroimaging and surgical outcome. Brain (2002) 2.17
Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages. J Immunol (2000) 2.17
A general strategy for isolation of endothelial cells from murine tissues. Characterization of two endothelial cell lines from the murine lung and subcutaneous sponge implants. Arterioscler Thromb Vasc Biol (1997) 2.15
Expression of adhesion molecules and chemotactic cytokines in cultured human mesothelial cells. J Exp Med (1992) 2.15
Prostacyclin synthesis induced in vascular cells by interleukin-1. Science (1985) 2.13
Monocyte chemotactic and activating factor gene expression induced in endothelial cells by IL-1 and tumor necrosis factor. J Immunol (1990) 2.10
Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J Clin Invest (2001) 2.10
Vitamin D3 affects differentiation, maturation, and function of human monocyte-derived dendritic cells. J Immunol (2000) 2.10
Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst (2000) 2.06
Migration of dendritic cells in response to formyl peptides, C5a, and a distinct set of chemokines. J Immunol (1995) 2.06
Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Am J Pathol (2000) 2.05
Receptor expression and responsiveness of human dendritic cells to a defined set of CC and CXC chemokines. J Immunol (1997) 2.02
Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer (2001) 2.02
Uncoupling of inflammatory chemokine receptors by IL-10: generation of functional decoys. Nat Immunol (2000) 2.01
Rapid killing of actinomycin D-treated tumor cells by human mononuclear cells. I. Effectors belong to the monocyte-macrophage lineage. J Immunol (1984) 2.01
Induction of natural killer cell migration by monocyte chemotactic protein-1, -2 and -3. Eur J Immunol (1994) 2.01
Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol (2002) 2.00
Bacterial lipopolysaccharide rapidly inhibits expression of C-C chemokine receptors in human monocytes. J Exp Med (1997) 1.97
European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol (1994) 1.97
Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component. J Biol Chem (1997) 1.97
Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines. Trends Immunol (2001) 1.95
Systemic anti-inflammatory mediators in COPD: increase in soluble interleukin 1 receptor II during treatment of exacerbations. Thorax (2001) 1.94
Molecular mechanisms of blood vessel formation. Trends Biochem Sci (1997) 1.93
The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer. J Clin Invest (1995) 1.91
Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin Exp Immunol (2012) 1.90
Peripheral neurotoxicity of taxol in patients previously treated with cisplatin. Cancer (1995) 1.88
Inflammatory bowel disease and intestinal cancer: a paradigm of the Yin-Yang interplay between inflammation and cancer. Oncogene (2010) 1.88
Cytolytic and cytostatic activity on tumor cells of circulating human monocytes. Int J Cancer (1979) 1.84
Regulation of the macrophage content of neoplasms by chemoattractants. Science (1983) 1.83
The type II 'decoy' receptor: a novel regulatory pathway for interleukin 1. Immunol Today (1994) 1.83
Recombinant human interleukin 5 is a selective eosinophil chemoattractant. Eur J Immunol (1989) 1.80
Interaction between fibrinogen and cultured endothelial cells. Induction of migration and specific binding. J Clin Invest (1985) 1.79
Progressive growth in immunodeficient mice and host cell recruitment by mouse endothelial cells transformed by polyoma middle-sized T antigen: implications for the pathogenesis of opportunistic vascular tumors. Proc Natl Acad Sci U S A (1994) 1.78
Interleukin 1-induced augmentation of experimental metastases from a human melanoma in nude mice. Cancer Res (1990) 1.77
Electroclinical, MRI and neuropathological study of 10 patients with nodular heterotopia, with surgical outcomes. Brain (2004) 1.73
Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients. Crit Care Med (2001) 1.73
Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int J Gynecol Cancer (2003) 1.70
Elevated cerebrospinal fluid levels of monocyte chemotactic protein-1 correlate with HIV-1 encephalitis and local viral replication. AIDS (1998) 1.70
Toll-like receptors: a growing family of immune receptors that are differentially expressed and regulated by different leukocytes. J Leukoc Biol (2000) 1.66
Expression and involvement of c-fos and c-jun protooncogenes in programmed cell death induced by growth factor deprivation in lymphoid cell lines. J Biol Chem (1992) 1.66
Glucocorticoids affect human dendritic cell differentiation and maturation. J Immunol (1999) 1.65
Inducible expression of PTX3, a new member of the pentraxin family, in human mononuclear phagocytes. Blood (1994) 1.64
Monokine production by microglial cell clones. Eur J Immunol (1989) 1.64
Oestrogens and obesity as risk factors for endometrial cancer in Italy. Int J Epidemiol (1982) 1.64
Cloning and characterization of a specific receptor for the novel CC chemokine MIP-3alpha from lung dendritic cells. J Exp Med (1997) 1.63
IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages. Eur J Immunol (1998) 1.63
The combination of yondelis and cisplatin is synergistic against human tumor xenografts. Eur J Cancer (2003) 1.63
Apoptosis. Biochemical events and relevance to cancer chemotherapy. FEBS Lett (1992) 1.62
The chemokine receptor switch paradigm and dendritic cell migration: its significance in tumor tissues. Immunol Rev (2000) 1.61
Intraoperative ultrasound during thoracoscopic procedures for solitary pulmonary nodules. Ann Thorac Surg (1999) 1.61
Interleukin 10 increases CCR5 expression and HIV infection in human monocytes. J Exp Med (1998) 1.58
The long pentraxin PTX3 binds to apoptotic cells and regulates their clearance by antigen-presenting dendritic cells. Blood (2000) 1.58
Monocyte function in intravenous drug abusers with lymphadenopathy syndrome and in patients with acquired immunodeficiency syndrome: selective impairment of chemotaxis. Clin Exp Immunol (1985) 1.57
Interleukin 1 stimulates platelet-activating factor production in cultured human endothelial cells. J Clin Invest (1986) 1.57
Expression of monocyte chemotactic protein and interleukin-8 by cytokine-activated human vascular smooth muscle cells. Arterioscler Thromb (1991) 1.57
Chemokine receptor expression and function in CD4+ T lymphocytes with regulatory activity. J Immunol (2001) 1.55